Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.

摘要: Until recently, 5 major studies have formed the basis for use of aspirin (acetylsalicylic acid) in primary prevention cardiovascular (CV) events. Despite these data, role has not been established firmly. Six randomized trials evaluated benefits CV events: British Doctors' Trial, Physicians' Health Study, Thrombosis Prevention Hypertension Optimal Treatment study, Primary Project, and Women's Study. The combined sample consists 47,293 subjects on 45,580 or placebo. A meta-analysis 6 assessed end points: total coronary heart disease (CHD), nonfatal myocardial infarction (MI), events, stroke, mortality, all-cause mortality. No covariate adjustment was performed appropriate tests treatment effect, heterogeneity, study size bias were applied. Using odds ratios confidence intervals, suggested superiority CHD, MI, events (p ≤0.001 each case), with a nonsignificant trend (0.07 0.05). Given cohort, decreased risk this large patient sample. In conclusion, but there no significant differences incidences stroke